
Why Are Lower-Cost Biosimilars So Hard for Patients to Get?
The House Ways and Means Committee heard testimony on hindrances to the expansion of use of biosimilars, medications close in structure and function to a patented biologic medicine. Witnesses at the April 8 hearing told legislators biosimilars save …